China Human Rabies Immunization After Dog Bite Exposure Manufacturer, Supplier, Factory

When a dog bite or scratch breaks the skin, the clock starts ticking. The Human Rabies Immunization After Dog Bite Exposure, manufactured by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. – a trusted China-based supplier – delivers rapid, reliable post‑exposure protection. With a 100% seroconversion rate by day 14 and a mean potency of 6.0 IU per dose (well above the WHO minimum of 2.5 IU), this vaccine addresses the single most urgent need: stopping the rabies virus before it reaches the brain. Available in both conventional and serum‑free Vero cell formulations, it has been administered in over 100 million doses globally, making it a proven choice for emergency clinics, public health programmes, and occupational health services.

Who Needs This Vaccine Most?

Post‑exposure cases – the primary indication

Anyone who sustains a dog bite, scratch, or mucous membrane contact with saliva from a suspected rabid animal is a candidate. WHO classifies exposures into Category II (minor abrasions without bleeding) and Category III (transdermal bites or mucosal contamination). For Category III, rabies immunoglobulin (20 IU/kg) must be given alongside the first dose.

High‑risk occupational groups

Veterinarians, animal handlers, laboratory staff, and field researchers who work with canines are also recommended for pre‑exposure prophylaxis, though post‑exposure use dominates.

Travelers to endemic regions

Individuals visiting areas with high dog‑mediated rabies incidence – particularly in parts of Asia, Africa, and South America – benefit from having this vaccine readily available in local healthcare facilities.

● Emergency departments – first‑line responders for bite victims.

● CDC‑affiliated clinics – manage large‑scale immunisation campaigns.

● Occupational health units – protect workers in animal‑related industries.

Formulation Technologies Compared

Two distinct versions of the Human Rabies Immunization After Dog Bite Exposure are offered to balance cost, safety, and clinical preferences. The conventional version uses the aG strain in standard Vero cell culture; the serum‑free version employs the PV‑2061 strain and eliminates bovine serum from all production steps – from cell revival to virus harvest – reducing allergy risks and batch variability. Both are freeze‑dried powders reconstituted to 1.0 mL for intramuscular injection.

Immune Response and Persistence

Seroconversion kinetics

Clinical data demonstrate that the Human Rabies Immunization After Dog Bite Exposure achieves 100% seroconversion by day 14 – the critical window when the virus is still travelling along peripheral nerves. The geometric mean antibody titres far exceed the WHO protective threshold of 0.5 IU/mL.

Long‑term protection

For the serum‑free version, immune persistence has been confirmed for over three months after the final dose, offering sustained reassurance even when follow‑up visits are missed. The conventional version also provides durable immunity, with booster responses readily triggered upon re‑exposure.

Cross‑neutralisation capacity

Antibodies raised against the vaccine strains effectively neutralise a broad spectrum of wild‑type rabies viruses, as verified by routine in vivo potency assays on every production batch.

● 100% seroconversion by day 14 – early protection when it matters most.

● Mean potency of 6.0 IU/dose – a 2.4‑fold safety margin above the minimum.

● Persistence beyond 3 months – reduces the risk of breakthrough infections.

Safety and Tolerability

Common adverse events

Post‑marketing surveillance covering over 100 million doses shows that reactions are predominantly mild and self‑limiting. Local pain, redness, or swelling occur in 10‑20% of recipients. Systemic effects like low‑grade fever, headache, or fatigue are reported in fewer than 5% of cases.

Serious events – extremely rare

No Grade 4 or above severe adverse reactions have been attributed to this vaccine. The serum‑free formulation further minimises allergy risks by eliminating bovine serum, a known sensitising agent.

Use in special populations

Pregnant and lactating women, immunocompromised patients, and individuals with acute febrile illness can safely receive the vaccine – the benefit of preventing rabies far outweighs any theoretical risk, as rabies is 100% fatal once symptoms appear.

● Preservative‑free (no thiomersal) – suitable for sensitive individuals.

● Serum‑free option – reduces allergic reactions and batch‑to‑batch variation.

● No contraindications in pregnancy or breastfeeding – confirmed by extensive real‑world data.

Administration Schedules and Flexibility

Standard 5‑dose Essen regimen

Administer 1.0 mL intramuscularly on days 0, 3, 7, 14, and 28. This is the most widely used schedule globally and is supported by both formulations.

Alternative 4‑dose WHO schedule

The serum‑free version also supports the abbreviated regimen (days 0, 3, 7, and 14), which reduces clinic visits and improves patient adherence, particularly in remote or resource‑limited settings.

Practical administration tips

Inject into the deltoid muscle for adults and older children; use the anterolateral thigh for infants. The lyophilised vaccine must be reconstituted immediately with the supplied diluent and used within a few hours if kept at 2‑8°C. Strict cold‑chain (2‑8°C, no freezing) is mandatory throughout the 36‑month shelf life.

● Flexibility in schedule – choose the regimen that fits your programme needs.

● Easy reconstitution and injection – designed for busy clinical settings.

● Long shelf life – reduces waste and simplifies inventory management.

Supply Chain and Procurement Advantages

As the second‑largest rabies vaccine manufacturer worldwide, AIM Vaccine ensures a stable, scalable supply of the Human Rabies Immunization After Dog Bite Exposure. Annual production capacity stands at approximately 22 million doses, supported by four wholly‑owned licensed subsidiaries and a dedicated workforce of 1,501 employees. The company serves over 2,800 district and county CDCs across China and exports to more than 20 countries, including Pakistan, Kenya, Egypt, and nations across Southeast Asia, Central Asia, and South America.

● Bulk purchasing – flexible order quantities with priority scheduling.

● Customised packaging – options for government tenders and NGO programmes.

● End‑to‑end logistics – temperature‑controlled shipping with real‑time monitoring.

● Regulatory support – assistance with dossiers, import permits, and local registration.

Quality Systems and Regulatory Status

Every batch is manufactured under GMP‑certified conditions, with the most recent certification granted in December 2025. The conventional version holds National Drug Approval Number S20073014; its production lines undergo annual surveillance, follow‑up, and vaccine‑specific patrol inspections by China’s NMPA. The company is one of only two Chinese human vaccine manufacturers with a P3 laboratory, reflecting advanced biosafety and R&D capabilities. The serum‑free version has completed Phase III trials and received marketing application acceptance (CXSS2500044), positioning it to become the world’s first licensed serum‑free rabies vaccine.

● Stringent QC – in vivo potency, sterility, endotoxin, and residual DNA testing.

● WHO prequalification pathway – alignment with international standards.

● Track record – over 100 million doses distributed with consistent quality.

Frequently Asked Questions

What is the maximum delay allowed before starting vaccination?

Answer: Ideally start within 24 hours, but even if days or weeks have passed, initiation is still strongly recommended because rabies incubation can be prolonged (weeks to years). There is no upper limit – as long as symptoms are absent, prophylaxis is always indicated.

Can I switch between conventional and serum‑free versions during the same course?

Answer: Both formulations induce similar neutralising antibody responses, and available evidence supports interchangeability without loss of efficacy. However, for consistency, it is preferable to complete the entire schedule with the same product.

Is the vaccine safe for pregnant women?

Answer: Yes, because rabies is invariably fatal, there are no contraindications during pregnancy. No adverse foetal effects have been reported with inactivated rabies vaccines. Pregnant women should receive the vaccine if exposed, in consultation with their healthcare provider.

How should the vaccine be stored during transport?

Answer: The lyophilised vaccine must be kept at 2‑8°C, protected from light, and never frozen. Transport must use validated refrigerated containers with continuous temperature loggers. Reconstituted vaccine should be used immediately or within a few hours if refrigerated.

Which formulation is more cost‑effective for mass procurement?

Answer: The conventional version offers lower unit cost due to mature manufacturing, making it ideal for budget‑constrained programmes. The serum‑free version, while slightly higher in price, delivers added safety benefits (zero bovine serum) and is preferred for markets with stringent purity demands. Both are competitively priced for international tenders.

Partner with a Proven Manufacturer

When every minute counts, you need a vaccine that is ready when you are – and a supplier that understands urgency. AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. combines decades of experience, cutting‑edge technology, and a customer‑centric approach. Whether you procure the Human Rabies Immunization After Dog Bite Exposure for emergency stockpiles, routine clinic use, or large‑scale campaigns, our team provides full‑cycle support – from regulatory documentation and customs clearance to logistics coordination and post‑shipment technical advice. Choose reliability, choose safety, choose AIM Honor – your trusted partner in rabies elimination.